Journal of Clinical Oncology
Articles in this Issue
Early peripheral Treg expansion after SBRT combined with low-dose radiotherapy to predict subsequent immune checkpoint inhibitor responses in patients with metastatic lung or gastrointestinal cancers.
2652 Background: This study aims to explore the potential therapeutic advantages of combining stereotactic body radiation therapy (SBRT) and low-dose radi...
Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial.
7540 Background: The combination of a proteasome inhibitor (PI) with lenalidomide (R) and dex (d) has been a common initial therapy for newly diagnosed my...
Survival outcomes in gynecologic melanomas: A population based analysis.
e17656 Background: Gynecologic melanomas are rare and aggressive malignancies arising in the vulva, vagina, cervix, uterus, and ovary. Unlike cutaneous me...
A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216).
4187 Background: The PREDICT trial, a recent phase IIIb/IV study, aimed to address the critical need for improved personalized treatment strategies in adv...
Survival impact of adjuvant treatment in resected stage III cutaneous melanoma patients: Results from a real-life cohort study (TAMARIS).
9576 Background: Anti-PD-1 immunotherapies and BRAF+MEK inhibitors (BRAFi/MEKi) (specifically for BRAF V600E/K-mutant melanoma) have been shown to improve...
Efficacy of neoadjuvant combination immune checkpoint inhibitor therapy in patients with resectable high grade melanomas: A systematic review and meta analysis of randomised control trials.
e21512 Background: The standard treatment for resectable, macroscopic stage 3 melanoma is Surgery followed by adjuvant therapy but neoadjuvant combination...
Trastuzumab-pertuzumab combined with taxanes or eribulin in HER2-positive breast cancer: A single-arm meta-analysis of RCTs.
e13019 Background: Trastuzumab-pertuzumab combined with taxanes or eribulin has emerged as a promising therapeutic regimen for HER2-positive breast cancer...
A review of additional primary cancers in breast cancer patients from a tumor registry of a large teaching hospital.
e12529 Background: While advancements in healthcare access, screening, early detection, and treatment have enhanced survival rates and reduced mortality,...
Trust and communication among sexual and gender minority (SGM) cancer survivors.
1611 Background: Trust and effective communication in healthcare are essential for delivering high-quality cancer care, especially for marginalized groups...
PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [ <sup>177</sup> Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC).
TPS5127 Background: Androgen deprivation therapy (ADT) ± androgen receptor pathway inhibitor therapy is a primary treatment for metastatic hormone-sensiti...
Molecular diversity in neuroendocrine tumors: A house divided.
e15170 Background: Despite significant morphological overlap between sub-groups, significant clinical heterogeneity is the hallmark of NENs. We sought to...
First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.
3028 Background: Cancer Associated Fibroblasts (CAFs) are key components of tumor microenvironment and have immunosuppressive functions. FAP is expressed...
Preliminary findings from the ALVA ePRO Platform pilot study: A novel approach to collecting quality of dying and death data among informal caregivers in palliative care.
11128 Background: Quality of Dying and Death (QODD) is a pivotal outcome in end-of-life care, yet traditional data collection methods, such as phone calls...
Evolving mortality trends in waldenstrom marcroglobulinemia: A 21 year analysis (1999-2020) using the CDC WONDER database.
e22546 Background: Waldenström Macroglobulinemia (WM) is an incurable B-cell lymphoproliferative disorder characterized by a rising incidence, particularl...
Implementation of a pre-treatment readiness tool for soft tissue and bone sarcoma.
e24072 Background: There is limited data on assessing a patient’s social needs prior to starting treatment, specifically in sarcoma. There is an extensive...
ALK-positive anaplastic large cell lymphoma: Statistics and survival trends.
7078 Background: Anaplastic lymphoma kinase positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare subtype of peripheral T-cell lymphoma, character...
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.
TPS8655 Background: c-Met (MET) protein expression is frequently increased in NSCLC and is associated with poor prognosis. 24% of pts with NSQ...
Real-world outcomes in patients living with HIV with lung cancer and treated with immune checkpoint inhibitors.
11156 Background: Lung cancer is one of the most common non-AIDS defining cancers in People Living with HIV (PLWH) and a leading cause of cancer death in...
The risk of venous and arterial thrombosis in polycythemia vera patients with secondary malignancies.
e18599 Background: Polycythemia vera (PCV) is a myeloproliferative neoplasm defined by the clonal proliferation of hematopoietic progenitor cells. PCV is...
Venetoclax duration outcomes analysis in MDS/AML within a community hospital.
e18511 Background: Hypomethylating agents (HMA) and venetoclax (Ven) are routinely used in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)...
Development of a comprehensive cfDNA methylation signature for prognostic, predictive, and diagnostic applications in pancreatic ductal adenocarcinoma (PDA).
4150 Background: Blood-based biomarkers are promising for predicting outcomes in pancreatic ductal adenocarcinoma (PDA) and could pave the way for develop...
Liposomal irinotecan together with vincristine and temozolomide (NALIRI-VT) for patients with relapsed or refractory Ewing sarcoma: A two-cohort, phase 1a/1b study.
11518 Background: To define the safety and preliminary efficacy of liposomal irinotecan together with vincristine and temozolomide in children and adults...
A Bayesian population-based framework for detecting hyperprogressive disease on cancer immunotherapies.
2665 Background: Hyperprogressive Disease (HPD), defined as an unexpected treatment-induced rapid increase in tumor growth rate relative to the tumor burd...
The relationship between PRR11 expression and prognosis in early ER+/HER2 low breast cancer.
e15154 Background: We aimed to investigate the prognostic value of proline-rich protein 11 (PRR11) expression in early ER+ / HER2 'low'...
AI-based predictive tool for identifying druggable mutations in lung cancer using nationwide comprehensive genomic profiling data.
e20642 Background: Comprehensive genomic profiling (CGP) plays a pivotal role in precision medicine. However, the low probability of discovering mutation-...